AbbVie Invests €150 Million in New Research and Development Facility in Germany
Introduction
AbbVie has initiated the construction of its new central research facility, "LUnA", at its main campus in Ludwigshafen, Rhineland-Palatinate, Germany.
Features
This state-of-the-art research and laboratory building represents a significant investment of approximately €150 million, solidifying Ludwigshafen as AbbVie's second largest global R&D location.
The facility is designed to house more than 300 researchers and scientists, equipped with modern and sustainable infrastructure features.
These include advanced laboratories and flexible workspaces aimed at fostering greater scientific collaboration across different research domains.
The integration of automation and digital research capabilities underscores AbbVie's commitment to advancing cutting-edge research in areas such as oncology, neuroscience, and immunology.
This initiative not only enhances AbbVie's research capabilities but also reinforces Rhineland-Palatinate's position as a leading hub for biotechnology and life sciences.
The construction project aligns with Germany's broader pharmaceutical strategy and aims to create optimal conditions for future research and development endeavors.
Scheduled for completion in 2027, LUnA is expected to play a pivotal role in AbbVie's global research network, supporting the company's mission to develop transformative therapies for serious diseases.
This signifies a milestone in AbbVie's ongoing partnership with Germany. This expansion underscores AbbVie's long-term commitment to Ludwigshafen, where it has invested significantly since 2020 to strengthen its capabilities in research, development, and pharmaceutical manufacturing.
Specification
Name New central research
Type New Construction
Year 2027
